Pharmaceutical

“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Nov 23, 2024 - 06:00
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
Read the original article

Tags:

Previous Article

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

Next Article

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Newly launched Calluna raises $81m to advance monoclona...

Jan 23, 2024

STAT+: Moderna CEO made $398 million in 2022, but still pledges to give most to charity

STAT+: Moderna CEO made $398 million in 2022, but still...

Mar 19, 2023

Kaiser Permanente reaches tentative agreement with workers

Kaiser Permanente reaches tentative agreement with workers

Oct 14, 2023